tetano
Editor, Senior Moderator
J Clin Med
. 2023 Oct 26;12(21):6772.
doi: 10.3390/jcm12216772. Serum KL-6 as a Candidate Predictor of Outcome in Patients with SARS-CoV-2 Pneumonia
Simone Kattner[SUP] 1 [/SUP], Sivagurunathan Sutharsan[SUP] 2 [/SUP], Marc Moritz Berger[SUP] 1 [/SUP], Andreas Limmer[SUP] 3 [/SUP], Lutz-Bernhard Jehn[SUP] 2 [/SUP], Frank Herbstreit[SUP] 1 [/SUP], Thorsten Brenner[SUP] 1 [/SUP], Christian Taube[SUP] 2 [/SUP], Francesco Bonella[SUP] 2 [/SUP]
Affiliations
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-infection is associated with an extremely variable disease course. When interstitial pneumonia (IP) occurs, it can lead to acute respiratory distress syndrome and death. Serum Krebs von den Lungen-6 (KL-6) is an established marker of IP, but its role as a marker of SARS-CoV-2 pneumonia is debated. This bicentric study included 157 patients with SARS-CoV-2 pneumonia. The WHO Ordinal Scale for Clinical Improvement (0-10 points) was used to classify the clinical course. Serum samples were collected at admission, and on days 3 and 7 of hospitalization. KL-6 was measured by using automated chemiluminescence immunoassay. A total of 68 patients developed a severe SARS-CoV-2 pneumonia, 135 of them required oxygen, and 15 died during hospitalization. The patients requiring non-invasive ventilation, invasive ventilation, or extracorporeal membrane oxygenation had significantly higher serum KL-6 levels at admission. The serum KL-6 levels were tendentially higher in patients who died than in those who survived. Logistic regression identified serum KL-6 at a cut-off of 335 U/mL at admission as a significant predictor of severe SARS-CoV-2 pneumonia outcome. Serum KL-6 seems to be a candidate biomarker for the clinical routine to stratify patients with SARS-CoV-2 pneumonia for the risk of a severe disease outcome or death.
Keywords: COVID-19; KL-6; SARS-CoV-2 pneumonia; biomarker; disease outcome.
. 2023 Oct 26;12(21):6772.
doi: 10.3390/jcm12216772. Serum KL-6 as a Candidate Predictor of Outcome in Patients with SARS-CoV-2 Pneumonia
Simone Kattner[SUP] 1 [/SUP], Sivagurunathan Sutharsan[SUP] 2 [/SUP], Marc Moritz Berger[SUP] 1 [/SUP], Andreas Limmer[SUP] 3 [/SUP], Lutz-Bernhard Jehn[SUP] 2 [/SUP], Frank Herbstreit[SUP] 1 [/SUP], Thorsten Brenner[SUP] 1 [/SUP], Christian Taube[SUP] 2 [/SUP], Francesco Bonella[SUP] 2 [/SUP]
Affiliations
- PMID: 37959236
- DOI: 10.3390/jcm12216772
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-infection is associated with an extremely variable disease course. When interstitial pneumonia (IP) occurs, it can lead to acute respiratory distress syndrome and death. Serum Krebs von den Lungen-6 (KL-6) is an established marker of IP, but its role as a marker of SARS-CoV-2 pneumonia is debated. This bicentric study included 157 patients with SARS-CoV-2 pneumonia. The WHO Ordinal Scale for Clinical Improvement (0-10 points) was used to classify the clinical course. Serum samples were collected at admission, and on days 3 and 7 of hospitalization. KL-6 was measured by using automated chemiluminescence immunoassay. A total of 68 patients developed a severe SARS-CoV-2 pneumonia, 135 of them required oxygen, and 15 died during hospitalization. The patients requiring non-invasive ventilation, invasive ventilation, or extracorporeal membrane oxygenation had significantly higher serum KL-6 levels at admission. The serum KL-6 levels were tendentially higher in patients who died than in those who survived. Logistic regression identified serum KL-6 at a cut-off of 335 U/mL at admission as a significant predictor of severe SARS-CoV-2 pneumonia outcome. Serum KL-6 seems to be a candidate biomarker for the clinical routine to stratify patients with SARS-CoV-2 pneumonia for the risk of a severe disease outcome or death.
Keywords: COVID-19; KL-6; SARS-CoV-2 pneumonia; biomarker; disease outcome.